August 31, 2008- Avandia has been the subject of widespread speculation that has brought drug manufacturer GlaxoSmithKline under fire for product liability claims. The drug, used to treat Type 2 diabetes, has been linked to cardiovascular deaths and serious health conditions. More than a dozen research trials revealed that patients who took the drug had more than a 40% higher chance of heart attack, and nearly a 65% higher chance of cardiovascular related death. Recent reports have claimed that the company was warned about the potential dangers approximately seven years before, but failed to significantly warn members of the public about the risks.
GlaxoSmithKline (GSK)has recently been the subject of even more negative attention for claims that the company had purposely targeted African Americans in marketing campaigns, which in effect put them at greater risk of being harmed by the drug. The targeted campaigns were strategically designed to market the product to African Americans, because of the higher incidence of Type 2 diabetes among members of this group. Renowned African American singer and actress, Della Reese, was hired as spokesperson for the drug from 2004-2006.
The marketing strategy is reported to pose even more problems for the manufacturing giant in the wake of increased public awareness of Avandia’s risks. The drug has produced an estimated $3 billion in revenue each year and after eight years on the market has becoming the top selling diabetes medication in the world. Avandia, which was once praised by the African American community and used to raise awareness about this disease, which affects such large numbers within their community, has become the target of accusations that GSK has continued to target this group despite being aware of Avandia’s dangers. As a result, an increase in the number of potential lawsuits filed is anticipated.
New York Injury News / New York Injury News is an online injury news service.